Facile synthesis of novel calcium silicate hydrated-nylon 6/66 nanocomposites by solution mixing method.

In this article a facile and green procedure for the synthesis of novel calcium silicate hydrated-nylon 6/66 nanocomposites is proposed. Calcium silicate hydrate (CSH) was synthesized by a hydrolysis technique assisted by ultrasound and using sodium dodecyl sulphate (SDS) as surfactant. CSH-nylon 6/66 nanocomposites were obtained by a solution mixing method at CSH loadings of 2.5, 25, 50 and 75 weight percent (samples CA, CD, CB and CC, respectively). The synthesis of CSH was confirmed by DRX and ATR-FTIR techniques; the CSH sample presents as mesoporous with a diameter between 3.34 nm and 52.68 nm and an average size of 27.07 nm; the specific surface area of the CSH sample was 343.99 m2 g-1. The formation of the CSH-nylon 6/66 nanocomposites was confirmed by ATR-FTIR, SEM, XRD, TGA, DSC and XPS techniques. The crystallization and melting temperatures (T m and T c, respectively) of CSH-nylon 6/66 nanocomposites occur at a slightly lower temperatures than those of neat Ny 6/66. These results suggest a slight decrease of the crystallite size and crystallization rate of nylon 6/66. The fusion enthalpy (ΔH f) decreases with increase in CSH content in nylon 6/66, which can be associated to a good dispersion. The XRD peaks of the nylon 6/66 at 19.99° and 23.77° were displaced at slightly higher values of 2θ with the incorporation of CSH in the polymer forming nanocomposite materials.

(131)I treatment in Differentiated Thyroid Cancer and End-Stage Renal Disease.

PURPOSE: Radioiodine (RAI) is a cornerstone in the treatment of Differentiated Thyroid Cancer (DTC). In patients on haemodialysis due to End-Stage Renal Disease (ESRD), it must be used cautiously, considering the renal clearance of this radionuclide. Also, the safety of the procedure and subsequent long-term outcome is still not well defined. In 2001, we described a dosimetric method and short-term results in three patients, with a good safety profile. We hypothesize that our method is safe in a long-term scenario without compromising the prognosis of both renal and thyroid disease. MATERIAL AND METHODS: Descriptive-retrospective study. A systematic search was carried out using our clinical database from 2000 to 2014. INCLUSION CRITERIA: DTC and radioiodine treatment while on haemodialysis. EXCLUSION CRITERIA: peritoneal dialysis. RESULTS: Final sample n=9 patients (n=5 males), age 48 years (median age 51 years males, 67 years female group); n=8 papillary thyroid cancer, n=1 follicular thyroid cancer; n=5 lymph node invasion; n=1 metastatic disease. Median RAI dose administered on haemodialysis 100mCi. 7.5 years after radioiodine treatment on haemodialysis, n=7 deemed free of thyroid disease, n=1 persistent non-localised disease. No complications related to the procedure or other target organs were registered. After 3.25 years, n=4 patients underwent successful renal transplantation; n=4 patients did not meet transplantation criteria due to other conditions unrelated to the thyroid disease or its treatment. One patient died due to ischemic cardiomyopathy (free of thyroid disease). CONCLUSIONS: Radioiodine treatment during haemodialysis is a long-term, safe procedure without worsening prognosis of either renal or thyroid disease.

Iodine-131 treatment of thyroid papillary carcinoma in patients undergoing dialysis for chronic renal failure: a dosimetric method.

Until recently, the therapeutic protocol widely accepted for ablation of the thyroid remnant and for metastases of thyroid papillary carcinoma was the administration of 131I after surgery. However, at present, some data question the usefulness of such treatment in patients considered low risk. The treatment with radioiodine in patients suffering from end-stage renal disease (ESRD) undergoing hemodialysis requires controlled dosages and individualized administration guidelines. The need to include these patients on the waiting list for a renal transplantation, once they have overcome the disease, and the higher prevalence of thyroid carcinoma in ESRD patients makes this an increasingly significant problem. The cases reported in the literature are few and the therapeutic models followed are very difficult. In this paper we propose a therapeutic model that provides the highest thyroid ablative dosage, minimizing radiation exposure to the rest of the organs. The main difference between our protocol and that already described is the performance of daily hemodialysis during the first 5 days of treatment, as well as the administration of a dose of 131I equivalent to that administered to patients who show normal renal function.